Mental retardation

My congratulations for taking the initiative to approach the subject: the neurobiology of behavior and associated disorders.

I was very interested by the article on mental retardation by Vasconcelos. The article had an extensive bibliography, but, unfortunately it does not deal with Brazilian work. There is very good Brazilian work on this theme, such as that by our fellow pediatrician, the geneticist, Raquel Boy and the text written by Dr. Marcos José de Burle Aguiar, published in the book by Dr. Gerson Carakushansky (all from the clinical genetics department at SBP), in addition to the article by Dr. Juan Llerena.

It is difficult to write a synthesis on a subject as wide as mental retardation, but as a pediatrician I cannot omit to remind us that in our practice sequelae from neonatal asphyxia remain the greatest cause of mental retardation in Brazil. In countries that are little developed, such as ours, infectious diseases such as congenital cytomegalovirus are another important cause of mental retardation, further to underdiagnosis, since serum testing for diagnosis is not performed routinely by the SUS (Brazilian National Health System) in Brazil. To witness these facts it is enough to work at any maternity unit in the country. These items were little discussed in the item on the causes of mental retardation, despite being cited in the epidemiology item.

I would have liked to have read about the epidemiology of mental retardation in Brazil and not in California, since the journal in which the article was published is Brazilian.

With respect of the genetic causes, our colleague performed an excellent review, but in the item on the neurobiology of mental retardation the text contains superficial commentaries that do not explain Figure 1 well.

In the item on the causes of mental retardation, I understand the author to mean to highlight exposure to teratogens during the prenatal period and not toxins as one cause, is this correct? Still on this item, we have emphasis given to cases of lead poisoning, pointing out that there are no reports of the prevalence of this cause in Brazil, which leads us to believe that this is not such an important cause as to merit prominence, whereas the use of teratogens is an important cause and was not highlighted, in common with the sequelae of prematurity and postnatal asphyxia by varying causes, such as pneumonia, meningitis, post-heart surgery, brain damage from sickle-cell anemia, untreated hypoglycemia, which are the most common causes for treatment in the routine of a pediatrician.

Our colleague further cites a search run on the OMIM database returning 1,149 distinct syndromes having mental retardation as one of their symptoms, but why cite neurofibromatosis (NFB I) in a list of less than 50 syndromes when there are so many others to cite if the majority of patients with neurofibromatosis do not have mental retardation?

In the item on neurocutaneous disorders, I would like to know what executive dysfunction is. I further call attention to the classification by IQ, which is so debated and criticized, when there is a citation that 4-8% of the patients with NFB I have IQ < 70 and attention deficit. Would this attention deficit not be being confused with mental retardation or reducing the IQ results of these children?

We know that in fragile X syndrome the presence of FMR1 is more common than is FMR2, however, the author cites a study with a sample of 534 children (the disease has an incidence of 1:2,500) in which FMR1 was found in three cases and in which three additional cases of FMR2 were found. Is this incidence correct? In the database used and suggested by the author, Online Mendelian Inheritance in Man (http://www3.ncbi.nlm.nih.gov/omim/) is the information that cases of FMR2 are rare.

In the item on how to investigate mental retardation, the author suggests that few metabolic diseases cause MR in isolation with no other associated symptoms and due to the prevalence of 0-5% in children with MR, metabolic investigation should not be included in initial screening, despite citing that there is consensus that initial evaluation should include a karyotype with 500 band resolution due to the 4-34.1% rate of frequency of chromosomal anomalies in patients with mental retardation.

I hope that this conduct does not enjoy the consensus of the society of pediatrics, since we live in a country where the Guthrie test is not performed for all children and, in our clinical practice there are children who could have had their mental retardation avoided if a laboratory test had been performed early but wasn’t; not just for phenylketonuria, but also for other treatable inborn errors of metabolism (IEM) and we could avoid such mental retardation. Inducing pediatricians to believed that IEM are rare is an error because, taken together they are common. Few pediatricians diagnose IEM cases, which may go more unnoticed than do chromosomopathy.

IF IEM do not have mental retardation in isolation as a characteristic, in the majority of cases chromosomopathies also do not cause mental retardation in isolation, while the propedeutic for IEM diagnosis is cheaper and easier to obtain than a high-resolution karyotype in Brazil.

We should concern ourselves with not copying foreign models without valorizing the reality of those who care for patients with mental retardation in practice.

Concluding, I would have liked to have read a little on prognosis, since in the item on treatment we have avant-garde procedures without end while in the last paragraph there is a comment on the use of a drug for insomnia with
adolescents with mental retardation, but there is no comment on whether it should be employed or if results were good). I am grateful for the opportunity to discuss these subjects, which would not be possible if we did not have the Jornal de Pediatria, of such excellent quality.

Erlane Marques Ribeiro
MSc. Professor, Faculdade de Medicina de Juazeiro do Norte. Geneticist physician, Hospital Geral César Cals and Hospital Infantil Albert Sabin. E-mail: erlane@genecom.com.br

References

Author’s reply

We are grateful to Professor Erlane Marques Ribeiro for her interest in our recently published article on mental retardation (MR).1 We feel that we have a duty to clarify certain points emphasized by the professor:

- She claims that the bibliography does not contain Brazilian work. However, careful reading of the references will reveal that numbers 25, 40, 53 and 57 are by domestic authors. The study by Felix et al. (ref. 40) describes the etiology of a series of MR cases and was discussed on page S75.

- Professor Erlane did not like reading about the epidemiology of MR in California. We hope that she has read about the connection between folic acid deficiency and neural tube defects – despite the epidemiological data that document this association originating in Great Britain.2 We would also hope that the professor has read about sleeping position and the sudden infant death syndrome. Some of the principal studies that laid the foundations for the American Academy of Pediatrics’ Back to Sleep campaign in 1994 came from New Zealand3 and Tasmania.4 We do not agree with a supposedly patriotic selection of which epidemiological studies are important. In our frank opinion, nationalism doesn’t mix with science.

- She claims that the use of teratogens was not highlighted. However, the article contains an entire section and even an illustrative figure on fetal alcohol syndrome, which would appear to us to be the primary teratogen involved.

- In a review article on a subject as complex as MR, the criteria of prevalence should not be the only guide to authors’ choices. The reason that we did not describe “in detail” cerebral palsy, meningitis, etc. within the causes of MR was our certainty that an informed reader of a supplement on “neurobiology of behavior” from the Jornal de Pediatria does not need to read a review article on MR to clarify diagnosis in such cases.

- On the contrary to the claim Doctor Erlane makes, at no point does the article mention, or induce the reader to believe, that inborn errors of metabolism (IEM) are rare. We maintain our position – which, since the pediatrics society did not sign the article, is only that of the author – that a “complete” investigation into IEM is opportune during “initial” screening. We are in excellent company.5 Furthermore, our article proposed the rational and progressive selection of metabolic tests, as Table 2 (p. S79 in the article) showed, and also emphasized the merits of anamnesis and physical examination to the investigation.

- We do not believe that, “it is enough to work at any maternity unit in the country” to better understand the causes of MR, since it is impossible to define a diagnosis of MR with certainty during the neonatal period.5

- It is true that the intelligence quotient (IQ) test has been criticized, particularly in our country. We the exception of the reservations mentioned on page S80, our opinion is that it is very useful for evaluating children and adolescents with neuropsychiatric complaints. Not to mention the fact that the immense majority of scientific articles worldwide use an MR classification based on IQ scores.

- In our view, the article makes it very clear that mutations of the FMR1 gene are the most common cause of fragile X syndrome. Furthermore, we believe that the article by Mazzocco et al.,6 while dealing with preliminary results, raises a clinically important question in dealing with the large group of preschool children with delayed language development. They did not find any complete FMR2 mutation, but found very small alleies of this gene in three children – which is itself an excellent research theme for geneticists.

- Doctor Erlane laments that SUS (Brazilian National Health Service) does not perform serum testing on neonates for congenital cytomegalovirus diagnosis. However, in contrast with what the professor suggests, the literature has established that serum tests do not help to define a diagnosis of congenital CMV infection and that, in the best of hypotheses, they merely exclude one.7 We hope for the day when SUS offers virus identification in urine or saliva culture or polymerase chain reaction to detect antigens.

- The section on the neurobiology of MR presents the principal current concepts on the subject, which can be gone into in more depth by means of reading, for example, reference number 22. Figure 1 seemed to us to be self-explanatory: an informed reader would know that it shows a neuron and the “actors” of synaptic transmission, many of which were named in the text.
Dear Editor,

It was with great interest that we read the article published in the July/August 2004 issue on the neonatal use of corticosteroids. In the editorial that accompanied this article, it was mentioned that "...the use of antenatal corticosteroid therapy in preterm labor at less than 34 weeks reached 61%. As far as we know, this figure is much higher than in any other Latin American study," and, in addition to the BNRN, the Vermont-Oxford and NICHD were cited as examples of "multicentric networks".

There was, however, an omission in the form of the non-inclusion of the NEOCOSUR Collaborative Group, a neonatal network whose goal is to collect information, prospectively, on newborn babies weighing less than 1,500 g and their mothers. The network is made up of 16 neonatal units from five South-American countries (Argentina, Chile, Peru, Paraguay and Uruguay) and has accumulated data on, since 1997, a total of 3,812 preterm babies weighing less than 1,500 g at birth. We publish in scientific journals and have given several presentations at a variety of scientific meetings, Pediatric Academic Societies (PAS), Latin-American Pediatric Research Society (SLAIP - Sociedade Latino-americana de Pesquisa Pediátrica), Argentine Society of Pediatrics National Research Meetings (Encuentro Nacional de Investigación Pediátrica) and the Chilean Pediatric and Neonatology congresses (Congreso Chileno de Pediatria and the Congreso Chileno de Neonatologia).

The neonatal corticoid usage recorded on the NEOCOSUR database is, currently, 68.9% (51-100), greater than that reported in Montevideo, Uruguay, and of the study in question. These data confirm that, in our countries, the application of preventative measures, the effectiveness of which has already been proven in clinical trials, has spread to localized populations, even though we do still need to fight unceasingly to increase their use.

Carlos Grandi
PhD. Researcher, Perinatal Epidemiology and Biostatistics, Maternidade Sardá, Buenos Aires, Argentina. E-mail: cgrandi@intramed.net

José Ceriani Cernadas
Chief of the Department of Pediatrics, Hospital Italiano, Buenos Aires, Argentina. E-mail: jceriani@hitalba.edu.ar

References